INmune Bio Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
25.2%projected annual EPS growth
Analyst Coverage
4analysts covering
FY EPS (est.)
-$0.55next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Q3 2026 Earnings Release | 5 Nov 2026 |
| Q4 2026 / FY 2026 Earnings Release | 29 Mar 2027 |
Monitoring Framework
Key Performance Indicators
Cash and Cash Equivalents Quarterly21.4MTarget: Sufficient to fund operations through Q1 2027
Quarterly Net Loss Attributable to Common Stockholders Quarterly-5.4MTarget: Continued narrowing of losses through disciplined R&D and G&A spending
Quarterly R&D Expenses Quarterly3.6MTarget: Optimized clinical trial spending aligned with late-stage registrational pathways
Watch Items
- CORDStrom™ UK MHRA Marketing Authorization Application (MAA) SubmissionTrigger: Filing completion in early Q3 2026 (mid-summer)Action: Monitor regulatory press releases and filings for confirmation of submission and acceptance.
- CORDStrom™ US FDA Biologics License Application (BLA) SubmissionTrigger: Filing completion in Q4 2026Action: Track FDA communications and company updates regarding BLA submission readiness and Rare Pediatric Disease PRV eligibility.
- XPro1595 Phase 2b/3 Registrational Program Initiation & Strategic PartnershipsTrigger: Securing a strategic partner to fund and advance the integrated Phase 2b/3 trial in early Alzheimer's DiseaseAction: Evaluate corporate announcements for licensing, co-development, or joint venture agreements as the company does not plan to advance XPro independently.
Research as of 19 Jun 2026